Weight-Loss Drug Use Persists Despite Risks of Muscle Loss, ‘Yo-yo’ Cycling
LONDON – Individuals achieving notable weight loss and even visible abdominal definition through medications like Ozempic, Wegovy, and Mounjaro are increasingly continuing-or resuming-use despite emerging concerns about potential muscle loss, psychological impacts, and the likelihood of weight regain upon cessation, a new report reveals. The trend highlights a complex relationship with thes drugs, with some users viewing them as long-term maintenance rather than temporary aids.
The medications, intended for regular, continuous use under medical supervision, work by suppressing appetite and regulating blood sugar.Patient leaflets recommend weekly injections and gradual dose increases. However,experts warn that restrictive dieting combined with these drugs can led to disproportionate muscle loss. “Slim individuals on restrictive diets tend to lose muscle more than fat,” explains a medical professional cited in the report. “If they regain weight later, their body composition worsens.” This “yo-yo cycle” of weight loss and regain “raises the long-term risk of weight gain,” particularly when combined with intermittent drug use.
Beyond the physical consequences, psychological factors are also at play. Dr. Halpern notes observing patients who believe weight loss will equate to happiness and acceptance, expectations he deems unrealistic. Stopping the medication and experiencing weight return frequently enough leads to feelings of failure. The body’s natural resistance to long-term weight loss further complicates matters,with hunger hormones increasing and metabolism slowing down onc medication is stopped. “When you lose weight, your body doesn’t just say, ‘Great, job done,'” explains Dr. Cork. “Hunger hormones ramp up, your metabolism slows, and your body tries to restore what it sees as your natural point.”
The long-term nature of the drugs’ intended use is underscored by the fact that they are designed to suppress hunger signals, which the body attempts to counteract when the medication is discontinued. obesity is recognized as a chronic disease requiring ongoing management, yet current NHS guidelines in the UK limit weight-loss drug access to a maximum of two years.
Concerns over misuse, safety, and supply shortages have prompted regulatory responses.In early 2025, Britain’s General Pharmaceutical Council tightened restrictions on online pharmacies selling and prescribing the jabs, and Brazil implemented similar measures earlier this year.
Despite these risks and regulations, some users, like Gabriela and Andrew, report having no intention of stopping. “I think I’ve become addicted to it,” gabriela admits, while Andrew views the drug as a long-term commitment to his appearance, accepting it as a “relatively informed risk” and suggesting he might continue cycling on and off the medication for life.
